Cell-delivered entry inhibitors for HIV-1: CCR5 downregulation and blocking virus/membrane fusion in defending the host cell population

AIDS Patient Care and STDs

Volumn 30, Issue 12, 2016, Pages 545-550

  Symonds, Geoff ^a   Bartlett, Jeffrey S ^a   Kiem, Hans Peter ^b   Tsie, Marlene ^a   Breton, Louis ^a  

^a Calimmune Australia Inc   (United States)

^b USA   (United States)

Author keywords

Cal 1; CCR5; CD34; CD4; CXCR4; Gene therapy; HIV 1; Lentiviral vector; Stem cell; T cell

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; C46 HIV-1 FUSION INHIBITORY PEPTIDE; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; HYBRID PROTEIN; VIRUS RECEPTOR;

ARTICLE; CD34 SELECTION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL DEVELOPMENT PLAN; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE FUSION; MOUSE; NONHUMAN; PRIMATE; RECEPTOR DOWN REGULATION; SAFETY; VIRUS CELL INTERACTION; VIRUS LOAD; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); DOWN REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ADULT; ANIMALS; BIOLOGICAL THERAPY; CCR5 RECEPTOR ANTAGONISTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; DOWN-REGULATION; GENETIC THERAPY; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; RECOMBINANT FUSION PROTEINS; VIRAL LOAD;

EID: 85002669470     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0245     Document Type: Article

References (41)

1. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382: 722-725.
2. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998;62: 1507-1515.
3. de Silva E, Stumpf MP. HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett 2004;241:1-12.
4. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
5. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
6. Hutter G, Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: An update after 3 years and the search for patient no. 2. AIDS 2011;25:273-274.
7. Brown TR. I am the Berlin patient: A personal reflection. AIDS Res Hum Retroviruses 2015;31:2-3.
8. Pernet O, Yadav SS, An DS. Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev 2016;103:187-201.
9. World Health Organization. Immunization, Vaccines and Biologicals HIV/AIDS. 2016. Available at: www.who .int/mediacentre/factsheets (Last accessed August, 2016).
10. AIDS Clinical Trials Group. ACTG Clinical Trials. Available at: https://actgnetwork.org (Last accessed August, 2016).
11. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003;100:183-188.
12. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998;72:8150-8157.
13. Ranga U, Woffendin C, Verma S, et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 1998;95:1201-1206.
14. An DS, Qin FX, Auyeung VC, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006;14:494-504.
15. An DS, Donahue RE, Karnata M, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A 2007;104:13110-13115.
16. Calimmune, Inc. Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection. Clinical-Trials.gov 2012;NCT01734850.
17. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
18. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47:333-348.
19. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984-1985;312:763-767.
20. Weiss RA. Thirty years on: HIV receptor gymnastics and the prevention of infection. BMC Biol 2013; 11:57.
21. Barre-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol 2013; 11:877-883.
22. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011;117:2791-2799.
23. Hildinger M, Dittmar MT, Schult-Dietrich P, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001;75:3038-3042.
24. Burke BP, Levin BR, Zhang J, et al. Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol Ther Nucleic Acids 2015; 4:e236.
25. Wolstein O, Boyd M, Millington M, et al. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev 2014;1:11.
26. Li M, Li H, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hema-topoietic cell gene therapy. Ann N Y Acad Sci 2006; 1082:172-179.
27. Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 2003;13:303-312.
28. Baltimore D. Gene-therapy-intracellular immunization. Nature 1988;335:395-396.
29. Shimizu S, Kamata M, Kittipongdaja P, et al. Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet Vaccines Ther 2009; 7:8.
30. Anderson J, Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005; 2:1.
31. Peterson CW, Haworth KG, Burke BP, et al. Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev 2016;3:16007.
32. van Lunzen J, Glaunsinger T, Stahmer I, et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007;15:1024-1033.
33. Ringpis GE, Shimizu S, Arokium H, et al. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One 2012;7:e53492.
34. Younan PM, Polacino P, Kowalski JP, et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 2013;122:179-187.
35. Fred Hutchinson Cancer Research Center. Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients with HIV-Associated Lymphoma. ClinicalTrials.gov 2015; NCT02378922.
36. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonma-lignant diseases. JAMA 2008;299:925-936.
37. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008;14:59-66.
38. Kang HJ, Bartholomae CC, Paruzynski A, et al. Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial. Mol Ther 2011;19:2092-2101.
39. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: Clinical comparison of retroviral vectors and treatment plans. Blood 2012;120:3635-3646.
40. De Ravin SS, Wu X, Moir S, et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2016;8:335ra357.
41. Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemo-poietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: An ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016;388:476-487.